Status:
COMPLETED
Different Durations of Adjuvant Anastrozole Therapy After 2 to 3 Years Tamoxifen Therapy in Breast Cancer
Lead Sponsor:
Maastricht University Medical Center
Conditions:
Breast Cancer
Eligibility:
FEMALE
45-99 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to determine whether 6 years adjuvant anastrozole will improve the disease free survival compared to 3 years adjuvant anastrozole in postmenopausal hormone sensitive breas...
Eligibility Criteria
Inclusion
- postmenopausal patients with hormone receptor positive breast cancer who have already received 2 to 3 years of adjuvant tamoxifen, and who never had signs of loco-regional recurrences or distant metastasis
Exclusion
- Previous hormonal therapy as adjuvant breast cancer treatment besides tamoxifen.
- Previous history of invasive breast cancer within the last 10 years, other then the breast cancer that is currently treated with tamoxifen
Key Trial Info
Start Date :
June 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2022
Estimated Enrollment :
1914 Patients enrolled
Trial Details
Trial ID
NCT00301457
Start Date
June 1 2006
End Date
April 1 2022
Last Update
February 21 2023
Active Locations (67)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
's-Hertogenbosch, Netherlands
2
Research Site
Alkmaar, Netherlands
3
Research Site
Almelo, Netherlands
4
Research Site
Almere Stad, Netherlands